AMPLIFY：第二代BTK抑制剂，用于慢性淋巴细胞白血病的固定疗程治疗。

IF 12.8 Q1 MEDICINE, RESEARCH & EXPERIMENTAL

Med Pub Date : 2025-04-11 DOI:10.1016/j.medj.2025.100665

Stefano Molica

引用次数: 0

摘要

慢性淋巴细胞白血病（CLL）治疗的最新进展强调了固定时间（FD）策略，特别是venetoclax联合obinutuzumab或ibrutinib，现已得到ESMO指南的认可。AMPLIFY 3期试验强调了acalabrutinib-venetoclax联合治疗，显示出优越的无进展生存期和可管理的安全性这些发现支持FD方案作为一种范式转变，优化了一线CLL治疗的疗效、安全性和患者便利性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

AMPLIFY: A second-generation BTK inhibitor for fixed-duration therapy in chronic lymphocytic leukemia.

Recent advancements in chronic lymphocytic leukemia (CLL) treatment emphasize fixed-duration (FD) strategies, notably venetoclax with obinutuzumab or ibrutinib, now endorsed by ESMO guidelines. The AMPLIFY phase 3 trial highlights acalabrutinib-venetoclax combinations, demonstrating superior progression-free survival and manageable safety.¹ These findings support FD regimens as a paradigm shift, optimizing efficacy, safety, and patient convenience in frontline CLL therapy.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Med MEDICINE, RESEARCH & EXPERIMENTAL-

CiteScore

17.70

自引率

0.60%

发文量

102

期刊介绍： Med is a flagship medical journal published monthly by Cell Press, the global publisher of trusted and authoritative science journals including Cell, Cancer Cell, and Cell Reports Medicine. Our mission is to advance clinical research and practice by providing a communication forum for the publication of clinical trial results, innovative observations from longitudinal cohorts, and pioneering discoveries about disease mechanisms. The journal also encourages thought-leadership discussions among biomedical researchers, physicians, and other health scientists and stakeholders. Our goal is to improve health worldwide sustainably and ethically. Med publishes rigorously vetted original research and cutting-edge review and perspective articles on critical health issues globally and regionally. Our research section covers clinical case reports, first-in-human studies, large-scale clinical trials, population-based studies, as well as translational research work with the potential to change the course of medical research and improve clinical practice.